Increased serum levels of adhesion molecules ICAM-1 and VCAM-1 in systemic sclerosis are not specific for pulmonary manifestations.

Authors:
Vivek Thakkar
Vivek Thakkar
St Vincent's Hospital Melbourne
Australia
Karen A Patterson
Karen A Patterson
Flinders University
Bedford Park | Australia
Wendy Stevens
Wendy Stevens
University of the Witwatersrand
South Africa
Michelle Wilson
Michelle Wilson
Auckland City Hospital
Auckland | New Zealand
Janet Roddy
Janet Roddy
St Vincent's Hospital Melbourne
Australia
Joanne Sahhar
Joanne Sahhar
The University of Melbourne
Australia
Susanna Proudman
Susanna Proudman
Royal Adelaide Hospital
Adelaide | Australia
Pravin Hissaria
Pravin Hissaria
Royal Adelaide Hospital
Australia

Clin Rheumatol 2018 Jun 23;37(6):1563-1571. Epub 2018 Apr 23.

Department of Rheumatology, St Vincent's Hospital (Melbourne), 41 Parade, Fitzroy, VIC, 3065, Australia.

Studies suggest elevated serum intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) levels may be markers of pulmonary arterial hypertension in systemic sclerosis (SSc-PAH). We sought to evaluate whether ICAM-1 and VCAM-1 levels are useful screening biomarkers for incident SSc-PAH. In this cross-sectional study, four groups were selected from the Australian Scleroderma Cohort Study: group 1 (n = 15) had definite PAH; group 2 (n = 19) had interstitial lung disease (ILD); group 3 (n = 30) were SSc-controls; and group 4 (n = 34) were healthy controls. Serum ICAM-1 and VCAM-1 levels were measured using the Millipore Milliplex MAP Human 2-Plex Panel. There were no differences in ICAM-1 levels in the PAH versus ILD group (263.0 ± 85.4 vs 380.4 ± 168.3 ng/mL, p = 0.136), SSc-controls (263.0 ± 85.4 vs 253.1 ± 98.0 ng/mL, p = 1.00), or healthy controls (263.0 ± 85.4 vs 201.8 ± 57.2 ng/mL, p = 0.093). Similarly, there were no differences in VCAM-1 level in PAH versus ILD groups (1476.2 ± 434.9 vs 1424.8 ± 527.6 ng/mL, p = 1.00) and SSc-controls (1476.2 ± 434.9 vs 1409.5 ± 341.1 ng/mL, p = 1.00). SSc subjects had significantly higher levels of ICAM-1 (297.4 ± 134.0 vs 201.8 ± 57.2 ng/mL, p < 0.0001) and VCAM-1 compared to healthy controls (1432.7 ± 427.4 vs 1125.6 ± 273.4 ng/mL, p < 0.0001). Neither ICAM-1 nor VCAM-1 is a specific screening biomarker of SSc-PAH. Instead, increased levels of these adhesion molecules in SSc, irrespective of pulmonary complications, suggest that they may play a role in SSc pathogenesis.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10067-018-4081-7DOI Listing
June 2018
2 Reads

Publication Analysis

Top Keywords

vcam-1 levels
12
icam-1 vcam-1
12
pah versus
8
systemic sclerosis
8
healthy controls
8
ild group
8
versus ild
8
adhesion molecule-1
8
icam-1
6
levels
6
vcam-1
5
group
5
vcam-1 level
4
n = 19 interstitial
4
group n = 19
4
ild groups
4
level pah
4
disease ild
4
differences vcam-1
4
group n = 30
4

Similar Publications

Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension.

Ann Rheum Dis 2008 Aug 20;67(8):1121-6. Epub 2007 Nov 20.

Rheumatology Unit - DIMIMP, University of Bari, Bari, Italy.

Objectives: To study the expression of adhesion molecules in patients with systemic sclerosis (SSc) with and without pulmonary arterial hypertension (PAH) and the effects of therapy with the endothelin-1 (ET-1) receptor antagonist, bosentan.

Methods: In all, 35 patients with SSc and 25 healthy donors (HD) were selected for this study. Of 35 patients, 10 had isolated PAH assessed by Doppler echocardiography and treated with bosentan. Read More

View Article
August 2008

Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis.

Br J Rheumatol 1995 Nov;34(11):1048-54

Rheumatology Research Unit, Royal Free Hospital, London.

Microvascular damage occurs in systemic sclerosis (SSc) and is associated with increased expression of endothelial adhesion molecules, including intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and E-selectin. Elevated levels of the soluble circulating forms of these molecules have recently been reported in SSc. We have extended this observation by collecting serial serum samples from 12 patients with systemic sclerosis, at intervals between 4 and 12 months, through the course of their disease (mean period of observation 44 months). Read More

View Article
November 1995

Circulating levels of ICAM-1, VCAM-1, and MCP-1 are increased in haemodialysis patients: association with inflammation, dyslipidaemia, and vascular events.

Nephrol Dial Transplant 2002 Mar;17(3):435-41

Department of Nephrology, Hippokration General Hospital, Thessaloniki, Greece.

Background: Increased levels of circulating adhesion molecules and chemokines have been reported in haemodialysis (HD) patients but the influence of the HD membranes on their secretion, as well as their pathophysiological implications, remains largely unknown.

Methods: Circulating levels of intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and monocyte chemoattractant protein-1 (MCP-1) were measured by immunosorbent assay (ELISA) in 81 HD patients (45 male, mean age 57+/-13 years) and 35 normal subjects. All patients had been stabilized on renal replacement therapy for >3 months and were free of active infection. Read More

View Article
March 2002

The proadhesive phenotype of systemic sclerosis skin promotes myeloid cell adhesion via ICAM-1 and VCAM-1.

Rheumatology (Oxford) 2009 Jul 13;48(7):734-40. Epub 2009 May 13.

Department of Internal Medicine, University of Michigan Medical School, AnnArbor, MI, USA.

Objective: SSc is characterized by microvascular abnormalities and leucocyte infiltration. Previous studies have suggested a proadhesive phenotype in SSc skin, but the functional consequences of this phenotype are not fully understood. Molecules known to mediate leucocyte adhesion include those present at intracellular junctions, such as junctional adhesion molecule-B (JAM-B), JAM-C and CD99, as well as intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1). Read More

View Article
July 2009